Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
|
|
MAXCYTE, INC. (MXCT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/04/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 08/09/2023 |
8-K
| Quarterly results |
| 05/10/2023 |
8-K
| Quarterly results |
| 03/28/2023 |
8-K
| Quarterly results |
| 03/15/2023 |
8-K
| Quarterly results |
| 03/06/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 12/01/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"MaxCyte Appoints Patrick J. Balthrop as Non-Executive Director Rockville, MD, 1 December, 2022: MaxCyte, Inc., , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announces the appointment of Patrick J. Balthrop, Sr. to the company’ s Board of Directors as non-executive director with immediate effect. Mr. Balthrop is also appointed as non-executive member of the Nominating and Corporate Governance Committee. Mr. Balthrop has more than 35 years of experience in the healthcare sector, particularly in the life sciences segments of diagnostics, life science tools, and medical devices. He was CEO, Presiden..." |
|
| 11/09/2022 |
8-K
| Quarterly results |
| 08/10/2022 |
8-K
| Quarterly results |
| 06/30/2022 |
8-K
| Quarterly results |
| 05/09/2022 |
8-K
| Quarterly results |
| 04/12/2022 |
8-K
| Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment...|
Docs:
|
"MaxCyte Announces Departure of CFO and Appointment of Ron Holtz as Interim CFO, Announces Preliminary First Quarter 2022 Revenue GAITHERSBURG, MD, April 12, 2022 — MaxCyte, Inc., , a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that Amanda Murphy has resigned from her position as Chief Financial Officer, effective as of April 15, 2022, to pursue other interests. Ron Holtz, current Senior Vice President and Chief Accounting Officer, has been named Interim Chief Financial Officer effective upon Ms. Murphy’ s departure. Following her departure, Ms. Murphy intends to provide consulting services to ..." |
|
| 03/22/2022 |
8-K
| Quarterly results |
| 01/24/2022 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 11/10/2021 |
8-K
| Quarterly results|
Docs:
|
"MaxCyte Reports Third Quarter Financial Results GAITHERSBURG, MD, November 10, 2021 — MaxCyte, Inc., , a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced third quarter ended September 30, 2021 financial results. Third Quarter and Recent Highlights · Total revenue was $10.1 million in the third quarter of 2021, representing 50% growth compared to the same period in 2020. · Excluding Strategic Platform License Program-related revenue, revenue from cell therapy customers was $6.2 million for the third quarter, an increase of 38% compared to the same period in 2020. · SPL Program-r..." |
|
| 11/02/2021 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 10/01/2021 |
8-K
| Quarterly results |
| 09/17/2021 |
8-K
| Quarterly results |
| 08/04/2021 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits |
|
|